Clinical Trial: NCT04109729
Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | University of Utah |
| Information Provided By: | University of Utah |
| Last Update Posted: | 2026-06-01 |
Study Overview
Brief Summary
This is a phase 1, open label, prospective, non-randomized single arm study combining Radium-223 with nivolumab in men with metastatic castration resistant prostate cancer.
Official Title
A Phase IB Study of Nivolumab in Combination With Radium-223 in Men With Metastatic Castration Resistant Prostate Cancer
Conditions
Metastatic Castration-resistant Prostate Cancer
Intervention / Treatment
- Drug: Nivolumab
- Drug: Radium-223
Other Study ID Numbers
- HCI126006
Start Date (Actual)
2020-09-16
Primary Completion Date (Actual)
2026-04-28
Study Completion Date (Estimated)
2026-12
Enrollment (Estimated)
39
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | University of Utah |
| Information Provided By: | University of Utah |
| Last Update Posted: | 2026-06-01 |
Study Overview
Brief Summary
This is a phase 1, open label, prospective, non-randomized single arm study combining Radium-223 with nivolumab in men with metastatic castration resistant prostate cancer.
Official Title
A Phase IB Study of Nivolumab in Combination With Radium-223 in Men With Metastatic Castration Resistant Prostate Cancer
Conditions
Metastatic Castration-resistant Prostate Cancer
Intervention / Treatment
- Drug: Nivolumab
- Drug: Radium-223
Other Study ID Numbers
- HCI126006
Start Date (Actual)
2020-09-16
Primary Completion Date (Actual)
2026-04-28
Study Completion Date (Estimated)
2026-12
Enrollment (Estimated)
39
Study Type
Interventional
Phase
Phase 1